

( (S (NP-SBJ G.D. Searle & Co.)
     (VP said
         (SBAR 0
               (S (NP-SBJ the Food and Drug Administration)
                  (VP approved
                      (NP (NP the sale)
                          (PP of
                              (NP (NP Kerlone)
                                  ,
                                  (NP (NP a hypertension drug)
                                      (VP developed
                                          (NP *)
                                          (PP by
                                              (NP-LGS (NP a joint venture)
                                                      (PP between
                                                          (NP (NP Searle)
                                                              and
                                                              (NP a French concern))))))))))))))
     .))
( (S (NP-SBJ (NP Searle)
             ,
             (NP (NP a unit)
                 (PP of
                     (NP Monsanto Co.)))
             ,)
     (VP said
         (SBAR 0
               (S (NP-SBJ the `` beta-blocker '' high-blood-pressure drug
                          Kerlone)
                  (VP is
                      (NP-PRD (NP the first product)
			      (SBAR (WHNP-1 0)
				    (S (NP-SBJ *T*-1)
				       (VP to
					   (VP reach
					       (NP the market)
					       (PP through
						   (NP (NP Lorex Pharmaceuticals)
						       ,
						       (NP (NP the U.S. company)
							   (VP (ADVP jointly)
							       owned
							       (NP *)
							       (PP by
								   (NP-LGS (NP Searle)
									   and
									   (NP (NP Synthelabo)
									       ,
									       (NP (NP a French pharmaceutical concern)
										   (VP owned
										       (NP *)
										       (PP by
											   (NP-LGS (NP France 's)
												   L'Oreal S.A))))))))))))))))))))
     .))
